Coldrif Cough Syrup Banned in Madhya Pradesh, Tamil Nadu, and Kerala

CopilotPerplexityChatGPTDeepSeekGoogleGrokGemini

Three Indian states, Madhya Pradesh, Tamil Nadu, and Kerala, have officially banned the sale and distribution of Coldrif cough syrup. The decision follows growing safety concerns about the formulation and possible side effects associated with its ingredients.

Composition and Concerns

Coldrif syrup contains a combination of Paracetamol, Phenylephrine Hydrochloride, and Chlorpheniramine Maleate, commonly used to treat cold, cough, and nasal congestion. However, health authorities in these states reported that the syrup has been linked to adverse reactions in some patients, particularly children, prompting immediate action.

Officials stated that the ban is a preventive measure to ensure public safety until further testing and analysis are completed. Local drug controllers have been instructed to withdraw existing stock from pharmacies and wholesalers.

Government Action and Review

The move comes after health regulators conducted routine checks on cough syrups across multiple regions. State drug control departments are reportedly coordinating with the Central Drugs Standard Control Organization (CDSCO) to assess whether similar measures are needed at the national level.

A senior health department official from Tamil Nadu said, “The ban is a precautionary step. Samples have been sent for testing to verify the quality and composition of the product. Until we receive clear results, the sale and distribution will remain prohibited.”

Industry Response

Pharmaceutical distributors have been informed of the ban and asked to halt further supply. While the manufacturer has not issued a public statement yet, distributors in the affected states confirmed that they are complying with the order.

India has tightened scrutiny over pharmaceutical products following recent international concerns about the safety of certain cough syrups exported to African and Asian markets. Health experts say state-level bans like this highlight the growing importance of strict quality control in domestic drug manufacturing.

Public health authorities have urged consumers to avoid self-medication and consult doctors for safe alternatives while Coldrif remains under review.